Read the latest news from Northwestern University Feinberg School of Medicine’s Department of Medicine, Division of Gastroenterology and Hepatology. The links below take you to articles where you can learn more about our faculty’s latest achievements, awards, and honors.
Pandolfino Interviewed by USA Today
Dr. John Pandolfino he has a message for anyone thinking about eating their shirt: Don’t.
“As a nation, we’ve been following low-fat advice for years, but as a nation we are also becoming more and more obese,” explains lead study author Deirdre Tobias, a researcher in the division of preventive medicine at BWH. “It’s clear that the low-fat approach isn’t working.”
That’s the word from a new meta-analysis published in The Lancet Diabetes & Endocrinology. For the review, researchers from Brigham and Women’s Hospital and the Harvard T.H. Chan School of Public Health in Boston combed through 53 randomized control trials comparing the weight-loss outcomes of 68,128 participants who had followed a low-fat or higher-fat diet. The results: Low-fat diets were actually less effective than higher-fat eating strategies at helping people lose weight and keep it off for a year or more.
Dr. Lisa VanWagner Discusses Transplant Hepatology Program Improvement at AASLD Liver Meeting 2015“Over the past decade, we’ve seen an increase in the prevalence of liver disease in our country but, at the same time, we’ve not seen an increase in the number of physicians choosing to specialize in hepatology,” VanWagner told Healio.com/Hepatology. “As a group and a society at AASLD, we will talk about how we can improve and increase that workforce and how we can plan our training programs so we can produce effective transplant hepatologists so we can meet the needs of patients in the U.S.”
- "I tell my friends all the time that there's definitely a connection between the gut and the brain. There are many, many nerves in the gastrointestinal tract that, among other things, help you feel what's going on inside your gut. We're learning now that stress may heighten those sensations—that's why you get 'butterflies.' But it can also trigger real physical symptoms: For example, I often see patients who seem to have reflux disease, but when we do the appropriate tests, we can't make a diagnosis. The best treatment for their heartburn, then, is anything that will help them relax, like hypnosis or deep breathing. If that doesn't work, medications that calm the nerves in the gut, like low-dose antidepressants, may help. If you're having these types of symptoms and they don't respond to the usual over-the-counter treatments, talk to your doctor. Once you've gotten to the root of the problem, you can get the help you really need." —John Pandolfino, M.D., chief of the division of gastroenterology and hepatology at Northwestern University Feinberg School of Medicine in Chicago
Using motivational interviewing to engage patients, assess where they are in stages of behavioral changeThis month Bariatric Times features an article titled, “Talking to Patients About Bariatric Surgery: Guiding Meaningful Conversations and Evoking Commitment to Change,” by Gretchen E. Ames, PhD, ABPP; Matthew M. Clark, PhD, ABPP; Karen B. Grothe, PhD, ABPP; and Maria L. Collozo-Clavell, MD. The authors discuss motivational interviewing (MI), which they define as a person-centered guiding method of communication between healthcare provider and patient that elicits and strengthens the patient’s own reasons and motivation for change. "I think that all healthcare providers working with patients with obesity (e.g., surgeons, obesity medicine specialists, nurses, psychologists, dietitians) might find benefits in using this technique. I had heard about MI and then saw Robert F. Kushner, MD, MS, FACP, Professor of Medicine at Northwestern University Feinberg School of Medicine in Chicago, Illinois, put it in action with obesity management. During a presentation, he introduced the fundamental processes of MI: open-ended questions, affirmations, reflections, and summaries. He then showed a video that illustrated all of the techniques being employed in a conversation with a patient all within 15 minutes. You could see from his presentation that MI could be done to quickly and effectively engage patients." -Christopher Still, DO, FACN, FACP
"At week 32, ozanimod 1 mg showed significant improvements in clinical remission, clinical response and mucosal improvement compared to placebo. The increase in the proportion of patients in clinical remission at week 32 when compared to week 8 in the ozanimod groups suggests that longer treatment may be associated with improving and sustained response rates," Stephen B. Hanauer, MD, Clifford Joseph Barborka professor in medicine-gastroenterology and hepatology, Northwestern University Feinberg School of Medicine, Chicago, said during his presentation at the 2015 ACG conference. “This is somewhat similar to what we’ve seen with other lymphocyte-trafficking agents."
"Ozanimod was well tolerated with a favorable benefit-risk profile, which supports the planned phase 3 trial in ulcerative colitis and the phase 2 trial in Crohn’s disease,” Hanauer concluded.